Sonya Eremenco will lead C-Path’s PRO Consortium
TUCSON, Ariz., August 5, 2021— Critical Path Institute (C-Path) announced it has named Sonya Eremenco, M.A., as Executive Director of its Patient-Reported Outcome (PRO) Consortium. Eremenco joined C-Path in 2016 as Associate Director of the PRO Consortium and was promoted to Director in January 2021. In addition to her leadership roles with the PRO Consortium, she also served as Acting Director of the ePRO Consortium from September 2018 to May 2021.
“Since joining C-Path five years ago, Sonya has consistently and amply demonstrated she is more than capable of taking on the role that I have had the privilege to hold for more than 12 years,” said Stephen Joel Coons, Ph.D., Senior Vice President of the Clinical Outcome Assessment (COA) Program. “Based on her extensive experience and unwavering commitment to leveraging the voice of the patient in drug development, I have every confidence that Sonya will lead the PRO Consortium to new heights and significant accomplishments.”
As Executive Director of C-Path’s PRO Consortium, Eremenco will provide operational and scientific leadership that guides development and qualification of PRO measures and other COAs that will be publicly available for use in clinical trials where COA-based endpoints are used to support labeling claims.
Eremenco has more than 25 years of experience in the development and evaluation of PRO measures and other COAs, with a focus on multicultural development, linguistic validation and electronic implementation. Prior to joining C-Path, Eremenco served as Director of ePRO New Products at Evidera.
“I am honored to be taking on the leadership of the PRO Consortium at a time when patient-focused drug development is increasingly recognized as essential to ensuring that new medical products provide clinical benefit in terms of how patients feel, function and survive,” said Eremenco. “The PRO Consortium enables sponsors to collaborate pre-competitively to shape the drug development environment by creating robust measurement tools that all stakeholders can employ in clinical trials. I look forward to continuing this important work.”
Eremenco received her undergraduate degree in cultural anthropology with a concentration in linguistics from Duke University and earned a Master of Arts in cross-cultural communication from DePaul University.
For more information on C-Path’s PRO Consortium, visit: https://c-path.org/programs/proc.
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 56.5% funded by FDA/HHS, totaling $16,749,891, and 43.5% funded by non-government source(s), totaling $12,895,366. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government. For more information, please visit FDA.gov.
About C-Path
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.
Media Contact:
Kissy Black
C-Path
615.310.1894
kblack@c-path.org
